Nonerosive Reflux Disease

Global reflux esophagitis market: Latest market analysis presented





23 evaluated 85 NERD patients with the PPI test (omeprazole 40 mg daily) administered over a period of 14 days and demonstrated a 66% sensitivity in this group of patients. The PPI test consistently had a low specificity in GERD patients, specifically in NERD patients. The potential explanation for this phenomenon is the partial response to therapy of patients with functional heartburn, particularly those with a "sensitive esophagus." Top of page Treatment The goals of treatment in NERD should include acute and long-term relief of symptoms, prevention of symptom relapse, and improvement in quality of life. In general, therapeutic requirements for patients with NERD are similar to those for patients with erosive esophagitis. Proton pump inhibitors are the most efficacious therapeutic modality in NERD patients. Overall, complete symptom control is achievable in only 37.6% ( PPI symptomatic response pooled rate) of NERD patients as compared with 55% ( PPI symptomatic response pooled rate) of those with erosive esophagitis after 4 weeks of treatment with a standard dose PPI 74 ( Figure 4 ). The lower response rate to PPI therapy as observed in NERD patients is attributed to the heterogeneity of this group. Specifically, the functional heartburn patients demonstrate the lowest response rate to PPI once daily of all NERD patients. Download Power Point slide (322 KB ) Unfortunately, NERD patients are still considered as having just a mild form of GERD , a position still widely held by institutions and third-party payers. Consequently, prescribing a PPI is commonly discouraged, and many of the patients are treated with long-term H2-blockers. However, therapeutic studies with H2-blockers in NERD patients showed very limited response rate, not greater from what was expected from placebo. 56 Generally H2-blockers are ineffective in inhibiting meal-induced acid secretion and are associated with development of rapid tolerance. 75 Increased doses in nonresponders are associated with very modest therapeutic gain. look at here now http://www.nature.com/gimo/contents/pt1/full/gimo42.html
















This report provides information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease). Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Reflux Esophagitis (Gastroesophageal Reflux Disease). - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. sell more http://www.live-pr.com/en/global-reflux-esophagitis-market-latest-r1050287225.htm